Morgan Stanley’s SteadyMed Ltd STDY Stock Holding History

Morgan Stanley’s Portfolio STDY Stock Details STDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,320	Closed	-$24K	–	6952
2018 Q2	$24K	Buy	5,320 +4,320	+432%	+$17.6K	﹤0.01%	6114
2018 Q1	$3K	Hold	1,000	–	–	﹤0.01%	6481
2017 Q4	$4K	Hold	1,000	–	–	﹤0.01%	6380
2017 Q3	$3K	Sell	1,000 -1,000	-50%	-$5.32K	﹤0.01%	6384
2017 Q2	$13K	Hold	2,000	–	–	﹤0.01%	6189
2017 Q1	$12K	Buy	2,000 +1,000	+100%	+$3.34K	﹤0.01%	6203
2016 Q4	$3K	Hold	1,000	–	–	﹤0.01%	6360
2016 Q3	$4K	Hold	1,000	–	–	﹤0.01%	6294
2016 Q2	$3K	Hold	1,000	–	–	﹤0.01%	6331
2016 Q1	$2K	Hold	1,000	–	–	﹤0.01%	6428
2015 Q4	$3K	Buy	+1,000	New	+$3.01K	﹤0.01%	6478
2015 Q3	–	Sell	-24	Closed	–	–	6828
2015 Q2	$0	Buy	+24	New	+$194	﹤0.01%	6843

Other funds holding STDY

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return

HCMT

Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return

Morgan Stanley's STDY Position: Q3 2018 in Review

Morgan Stanley sold out of SteadyMed Ltd (STDY) in Q3 2018, closing a stake of 5,320 shares — an estimated $24K sold.

Morgan Stanley first reported a position in STDY in Q2 2015 and held it in 12 quarters. The position peaked at $24K in Q2 2018. 5 funds tracked by Wall St. Rank hold STDY as of Q3 2018.

Morgan Stanley reported no remaining SteadyMed Ltd position as of Q3 2018 after selling out during the quarter.
Morgan Stanley sold 5,320 SteadyMed Ltd shares in Q3 2018, an estimated $24K.
Morgan Stanley first reported a position in SteadyMed Ltd in Q2 2015 and held it in 12 quarters.
Morgan Stanley's SteadyMed Ltd position peaked at $24K in Q2 2018.
5 funds tracked by Wall St. Rank held SteadyMed Ltd as of Q3 2018.

Based on Morgan Stanley's 13F filing for Q3 2018, filed 14 Nov 2018.